Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) represents the most common form of pancreatic cancer with rising incidence in developing countries. Unfortunately, the overall 5-year survival rate is still less than 5%. The most frequent oncogenic mutations in PDAC are loss-of function mutations in p53 and g...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaccagnino, Angela, Managò, Antonella, Leanza, Luigi, Gontarewitz, Artur, Linder, Bernhard, Azzolini, Michele, Biasutto, Lucia, Zoratti, Mario, Peruzzo, Roberta, Legler, Karen, Trauzold, Anna, Kalthoff, Holger, Szabo, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503532/
https://www.ncbi.nlm.nih.gov/pubmed/27542263
http://dx.doi.org/10.18632/oncotarget.11299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503532/
https://www.ncbi.nlm.nih.gov/pubmed/27542263
http://dx.doi.org/10.18632/oncotarget.11299

Ejemplares similares